ADAP News and Press, Adaptimmune Therapeutics plc From 07/21/22

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before th...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...

There are some incredible deals in biotech right now. Three Fool.com contributors think Adaptimmune Therapeutics (NASDAQ: ADAP) , G1 Therapeutics (NASDAQ: GTHX) , and Axsome Therapeutics (NASDAQ: AXSM) are on the verge of a big move over the next couple of years. ...

SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%. A BLA filing for afami-cel for the treatment of patients with synovial sarcoma and MRCLS is expected in Q4 of 2022. The ...

Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. Specifically, the biotech's stock is currently up by a respectable 7.72% as of 2:05 p.m. ET Monday. To put this move into the proper cont...

Adaptimmune Therapeutics is a cell therapy company using their TCR-engineered T cells to take on various tumor types. Their leading program is MAGE-A4 which contains afami-cel, a TCR-engineered T cell that targets the MAGE-A4 CTA and is being tried in multiple tumors types. Adapti...

Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord Blood (CO) +18%. GreenBox (GBOX) +17%. Kopin (KOPN) +15%. Losers: N...

- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) - - Responses occurred across subgroups, with greater response rates associated with lower baseline tumor burden, fewer prior lines of therapy, and higher ...

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage biopharmaceutical company that specializes in T-cell therapies to treat cancer, jumped 13.4% on Tuesday. The company's shares are down more than 58% so far this year. The company reported positive proof-of-...

- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro - - Engineered TILs (ADP-TILIL7) intended to improve clinical responses, produced levels o...